First Candidate From SCYNEXIS’ Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof Of Concept In HCV-Infected Adults

Drug discovery company, SCYNEXIS, Inc., announced top-line results from a Phase 1b randomized, double-blind, placebo-controlled study of its lead oral antiviral drug candidate, SCY-635, in adult patients with chronic hepatitis C (HCV) infection. Treatment with SCY-635 was well tolerated and produced a clinically relevant reduction in plasma HCV RNA. Full results of the study will be presented in 2009.

More: continued here

Filed under: Liver Disease / Hepatitis on January 16th, 2009